Only healthy, strength-trained individuals are included in the study. People with physiological injuries or mental illnesses are not included.
Conditions
Interventions
Group 1: Creatine group: Firstly, there is a four-week familiarisation phase involving regular strength training. This is followed by a four-week strength training phase involving creatine supplementa
Sponsors
IST Hochschule für Management
Eligibility
Sex/Gender
All
Age
18 Years to 39 Years
Inclusion criteria
Inclusion criteria: All test subjects must be aged between 18 and 39 and have at least one year's experience of strength training (minimum of two sessions per week). Subjects must be free from injury and chronic illness. Subjects must not be taking any medication or anabolic steroids.
Exclusion criteria
Exclusion criteria: Orthopaedic abnormalities in the shoulder area and psychological abnormalities in the form of an eating disorder are not permitted. Furthermore, organ diseases that would contraindicate the use of creatine, such as liver and kidney diseases or cardiovascular disorders involving pacemakers, will exclude potential test subjects from participation. Acute injuries to the upper body also exclude potential test subjects from participating.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum strength (1RM) and body composition (fat-free mass, muscle mass, water balance, fat mass and body weight) were measured. These parameters were determined at the following points in time: - Baseline - 4 weeks after baseline (T1) - 4 weeks after baseline with creatine/placebo supplementation (T2) - after a subsequent 4-week phase (discontinue/continue creatine or discontinue/continue placebo) (T3/posttest) | — |
Secondary
| Measure | Time frame |
|---|---|
| Cognition (Flanker Test, Stoop Test). These parameters were determined at the following points in time: - Baseline - 4 weeks after baseline (T1) - 4 weeks after baseline with creatine/placebo supplementation (T2) - after a subsequent 4-week phase (discontinue/continue creatine or discontinue/continue placebo) (T3/posttest) | — |
Countries
Germany
Contacts
Public ContactTim Havers
IST Hochschule für Management
Outcome results
None listed